News

Targeted Oncology13d
FDA Approves IDE Application for Alpha DaRT in Recurrent Glioblastoma
The FDA has approved an investigational device exemption (IDE) application for the start of a pilot study evaluating the ...
Cure Today15d
FDA Approves Initiation of a New Trial in Recurrent Glioblastoma
The United States Food and Drug Administration (FDA) has approved an Investigational Device Exemption application to initiate a pilot study with Alpha DaRT for the treatment of patients with recurrent ...
Yahoo Finance14d
Alpha Tau Receives FDA Approval to Initiate a Trial for Patients with Recurrent Glioblastoma
application to initiate a pilot study for the treatment of patients with recurrent glioblastoma (GBM) using the Alpha DaRT technology. “This is very exciting news for patients suffering from ...
ADVFN1mon
Alpha Tau Announces Alpha DaRT Treatment of First Patient with Liver Metastases of Colorectal Cancer
We are encouraged by the early results of Alpha DaRT treatment in other tumor types and are hopeful that the Alpha DaRT treatment will offer better outcomes to these patients with such a ...
ADVFN1mon
Alpha Tau Announces Cornerstone Interim Data Across Multiple Clinical Trials to be Shared at R&D Update Day
In addition, no SAEs related to Alpha DaRT treatment were reported in these patients as of the data cutoff date of January 9, 2025. In today’s presentation, the clinicians will also review the ...
Business Insider14d
Alpha Tau Receives FDA Approval to Initiate a Trial for Patients with Recurrent Glioblastoma
DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT ®, announced today that the FDA has approved an Investigational Device Exemption (IDE) application to initiate a pilot ...
Alpha Tau receives FDA approval to start trial for patients with recurrent GBM
Medical announced that the FDA has approved an Investigational Device Exemption, IDE, application to initiate a pilot study ...